Advanced Science. Uncovering Risk.

Matching Patients to their optimal treatments through molecular age signatures

Clinicians often use a patient’s age to make treatment decisions in a wide range of clinical scenarios. However, chronological age is an unreliable predictor of individual’s risk posed by surgical procedures and therapeutic interventions. An individual’s rate of aging is strongly influenced by environmental, genetic, and lifestyle factors which are not accounted for by chronological age alone. In contrast, biomarkers of molecular age provide a snapshot of the overall health and resiliency of the body, thus allowing physicians to better know their patients and more accurately predict their health risks.

Molecular Age

HealthSpan Diagnostics has developed an assay that measures molecular age. Molecular age is personalized and based on genetic, lifestyle, and environmental factors. Individuals of the same age can have drastically different molecular ages and unique risk profiles.
Patient’s molecular age is more than just a number. It helps match patients to therapies and clinical trials — giving doctors and patients powerful actionable insights for navigating care.

AKI-SapereTM, is being clinically validated in a cardiovascular disease setting to identify patients  at high risk for acute kidney injury, adverse cardiac outcomes, rehospitalization and death.

P16 Testing:
Expression of p16 aging biomarker is a powerful predictor of patient frailty and is being clinically validated in multiple clincal settings.

Become a Partner

HealthSpan Dx is seeking partnerships with clinicians, pharma companies, and academic researchers that would benefit from our expertise in developing assays that incorporate molecular age measurements to uncover patient risk.